摘要
背景与目的贝伐单抗是针对VEGF的重组人源化单克隆抗体,2006年10月被美国FDA批准联合泰素卡铂化疗方案用于晚期非鳞型非小细胞肺癌的一线治疗。本文应用贝伐单抗联合泰素卡铂化疗方案,观察中国晚期肺癌患者应用贝伐单抗治疗的安全性。方法贝伐单抗应用15 mg/kg,化疗第1 d静点,以后每3周重复;联合化疗方案为紫杉醇:175 mg/m^2,d_1,卡铂:AUC=6,d_1,每3周重复。化疗应用4-6周期,贝伐单抗每3周应用直至病情进展。治疗过程中据NCI CTC 3.0版本评价不良反应级别、记录分析不良反应发生时间、治疗及转归。结果13例患者发生3级鼻出血1例、4级血栓栓塞1例,较常见不良反应为1或2级的鼻出血、咯血、高血压、蛋白尿等,均程度较轻可以耐受。结论贝伐单抗联合紫杉醇卡铂方案化疗一线治疗晚期肺癌多数患者耐受良好。
Background and objective Bevacizumab is a recombinant humanized monoclonal IgG1 antibody that selectively binds to and neutralizes the biologic activity of human vascular endothelial growth factor （VEGF）. Bevacizumab was approved by the U.S. Food and Drug Administration （FDA） in October 2006 for use in combination with carboplatin and paclitaxel for the initial treatment of patients with unresectable, locally advanced, recurrent, or metastatic, nonsquamous, non-small cell lung cancer （NSCLC）. The aim of this study is to observe the safety of bevacizumab therapy in combination with chemotherapy in Chinese patients with NSCLC. Methods Patients with advanced non-squamous NSCLC were treated with Bevacizumab 15 mg/kg, d1, repeated every 21 days until PD; Plus paclitaxel 175 mg/m2, on d1 and carboplatin AUC=6 on d1. The cycle was repeated every 21 days. Results One grade 3 epistaxis was observed in one patient. One grade 4 thrombosis was observed in one patient. 3/4-grade epistaxis and thrombosis was the most significant adverse events. Other adverse effects, such as hemoptysis, hypertension and proteinuria, were not severe and could be well tolerated. Conclusion Most chemotherapy-naive patients with advanced non-squamous NSCLC treated with bevacizumab in combination with paclitaxel and carboplatin have little adverse effects that can be well tolerated.
出处
《中国肺癌杂志》
CAS
2009年第3期231-235,共5页
Chinese Journal of Lung Cancer
关键词
贝伐单抗
肺肿瘤
安全性
Bevacizumab
Lung neoplasms
Safety
作者简介
通讯作者：武玮，E-mail：wuw07@yahoo．com．cn
